HC Wainwright & Co. Maintains Neutral on Zymeworks, Raises Price Target to $13

Benzinga · 03/10 17:04
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Neutral and raises the price target from $12 to $13.